Arun Sasikumar1, Ajith Joy, M R A Pillai, Raviteja Nanabala, Muhammed Anees K, P G Jayaprakash, Jayaprakash Madhavan, Suresh Nair. 1. From the *Department of Nuclear Medicine and PET/CT KIMS-DDNMRC, Trivandrum, Kerala; †Molecular Group of Companies, Puthuvype, Ernakulam, Kerala; ‡Department of Radiation Oncology, Regional Cancer Centre, Trivandrum, Kerala; §Department of Radiation Oncology, KIMS Cancer Centre, Trivandrum, Kerala; and ∥Department of Neurosurgery, Sree Chitra Tirunal Institute of Medical Sciences and Technology, Trivandrum, Kerala, India.
Abstract
OBJECTIVE: To evaluate the feasibility of using Ga PSMA-11 PET/CT for imaging brain lesions and its comparison with F-FDG. METHODS: Ten patients with brain lesions were included in the study. Five patients were treated cases of glioblastoma with suspected recurrence. F-FDG and Ga PSMA-11 brain scans were done for these patients. Five patients were sent for assessing the nature (primary lesion/metastasis) of space occupying lesion in brain. They underwent whole body F-FDG PET/CT scan and a primary site elsewhere in the body was ruled out. Subsequently they underwent Ga PSMA-11 brain PET/CT imaging. Target to background ratios (TBR) for the brain lesions were calculated using contralateral cerebellar uptake as background. RESULTS: In five treated cases of glioblastoma with suspected recurrence the findings of Ga PSMA-11 PET/CT showed good correlation with that of F-FDG PET/CT scan. Compared to the F-FDG, Ga PSMA-11 PET/CT showed better visualization of the recurrent lesion (presence/absence) owing to its significantly high TBR. Among the five cases evaluated for lesion characterization glioma and atypical meningioma patients showed higher SUVmax in the lesion with Ga PSMA-11 than with F-FDG and converse in cases of lymphoma. TBR was better with Ga PSMA PET/CT in all cases. CONCLUSION: Ga PSMA-11 PET/CT brain imaging is a potentially useful imaging tool in the evaluation of brain lesions. Absence of physiological uptake of Ga PSMA-11 in the normal brain parenchyma results in high TBR values and consequently better visualization of metabolically active disease in brain.
OBJECTIVE: To evaluate the feasibility of using GaPSMA-11 PET/CT for imaging brain lesions and its comparison with F-FDG. METHODS: Ten patients with brain lesions were included in the study. Five patients were treated cases of glioblastoma with suspected recurrence. F-FDG and GaPSMA-11 brain scans were done for these patients. Five patients were sent for assessing the nature (primary lesion/metastasis) of space occupying lesion in brain. They underwent whole body F-FDG PET/CT scan and a primary site elsewhere in the body was ruled out. Subsequently they underwent GaPSMA-11 brain PET/CT imaging. Target to background ratios (TBR) for the brain lesions were calculated using contralateral cerebellar uptake as background. RESULTS: In five treated cases of glioblastoma with suspected recurrence the findings of GaPSMA-11 PET/CT showed good correlation with that of F-FDG PET/CT scan. Compared to the F-FDG, GaPSMA-11 PET/CT showed better visualization of the recurrent lesion (presence/absence) owing to its significantly high TBR. Among the five cases evaluated for lesion characterization glioma and atypical meningiomapatients showed higher SUVmax in the lesion with GaPSMA-11 than with F-FDG and converse in cases of lymphoma. TBR was better with GaPSMA PET/CT in all cases. CONCLUSION:GaPSMA-11 PET/CT brain imaging is a potentially useful imaging tool in the evaluation of brain lesions. Absence of physiological uptake of GaPSMA-11 in the normal brain parenchyma results in high TBR values and consequently better visualization of metabolically active disease in brain.
Authors: Yafu Yin; Scott P Campbell; Mark C Markowski; Philip M Pierorazio; Martin G Pomper; Mohamad E Allaf; Steven P Rowe; Michael A Gorin Journal: Mol Imaging Biol Date: 2019-06 Impact factor: 3.488
Authors: Roberto Andres Salas Fragomeni; Joshua R Menke; Matthias Holdhoff; Clare Ferrigno; John Joseph Laterra; Lilja B Solnes; Mehrbod S Javadi; Zsolt Szabo; Martin G Pomper; Steven P Rowe Journal: Clin Nucl Med Date: 2017-10 Impact factor: 7.794
Authors: Marcus Unterrainer; Maximilian Niyazi; Viktoria Ruf; Peter Bartenstein; Nathalie L Albert Journal: Neuro Oncol Date: 2017-11-29 Impact factor: 12.300
Authors: Scott P Campbell; Alexander S Baras; Mark W Ball; Max Kates; Noah M Hahn; Trinity J Bivalacqua; Michael H Johnson; Martin G Pomper; Mohamad E Allaf; Steven P Rowe; Michael A Gorin Journal: Ann Nucl Med Date: 2017-10-24 Impact factor: 2.668
Authors: Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar Journal: Eur J Nucl Med Mol Imaging Date: 2018-01-15 Impact factor: 9.236
Authors: Thomas J W Klein Nulent; Robert J J van Es; Gerard C Krijger; Remco de Bree; Stefan M Willems; Bart de Keizer Journal: Eur J Nucl Med Mol Imaging Date: 2017-06-07 Impact factor: 9.236